Exosomes have recently exploded in popularity, with companies developing exosome-based diagnostics, therapeutics, and cosmeceuticals. Although they were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits. [Read more…]
Basecamp Research Raises $140M to Advance AI-Designed In Vivo Cell Therapies
NEWS PROVIDED BY Basecamp Research, Sept 23, 2026, 09:06 ET
-
Oversubscribed Series C led by S32 with backing from NVIDIA, Menlo Ventures’ Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI, and True Ventures.
-
Funding will advance a pipeline of EDEN-designed therapeutics, starting with in vivo cell therapy, and expand pharmaceutical partnerships
-
The company has demonstrated strong preclinical results across multiple modalities and disease areas
Made Scientific Expands U.S. GMP Cell Therapy Network with 85,000 Sq. Ft. Pennsylvania Acquisition — Operational on Day One
NEWS PROVIDED BY Made Scientific, Inc., Sept 21, 2026, 09:06 ET
Facility brings Made Scientific’s U.S. East Coast footprint to 145,000 sq. ft. and 15 qualified GMP manufacturing suites
PRINCETON, N.J., Sept. 21, 2026 — Made Scientific, Inc., a leading U.S.-based clinical- and commercial-stage cell therapy contract development and manufacturing organization (CDMO), today announced it has acquired an 85,000 sq. ft. clinical to commercial-scale cell therapy manufacturing facility in East Norriton, Pennsylvania, from National Resilience. The transaction closed on September 18, 2026. The facility is operational on close, eliminating the ramp-up and qualification timelines that follow a greenfield build — a critical advantage as therapies advance through late-stage development toward commercial launch. The site and its manufacturing team have executed 145 GMP batches to date across multiple autologous and allogeneic programs, including CAR-T and B-cell therapies. Sponsors can begin onboarding programs immediately, positioning therapies for 2027 clinical and commercial supply. [Read more…]
$600M in VC Funding. $1B Milestone Deals. The Exosome Market Is Accelerating.
It took just over three decades for exosomes to move from a laboratory curiosity to a validated biological system with real therapeutic potential. First formally named in 1981 and identified in sheep reticulocytes in 1983, exosomes weren’t seriously investigated for medical application until the late 2000s and early 2010s, once researchers discovered they could shuttle transferable mRNA and miRNA between cells. That shift was cemented in 2013, when the Nobel Prize in Physiology or Medicine was awarded to Rothman, Schekman, and Südhof for validating the mechanisms behind vesicular transport. [Read more…]
Designer Exosomes: How Engineered Vesicles Are Transforming Drug Delivery in 2027
In the evolving landscape of biomedical innovation, exosomes have emerged as one of the most promising tools for next-generation therapies. These nanoscale, membrane-bound vesicles, naturally secreted by cells, play a critical role in intercellular communication. Because of their inherent ability to shuttle biomolecules like RNA, proteins, and lipids between cells, exosomes have captivated the attention of researchers and biotech companies for their vast potential in therapeutic applications. [Read more…]
- 1
- 2
- 3
- …
- 339
- Next Page »